Elevalue Laboratories

Elevalue Laboratories

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Elevalue Laboratories is a privately held, specialized analytical services provider dedicated to the cell and gene therapy (CGT) market. The company operates as a one-stop shop for CGT developers, offering comprehensive assay development, qualification, validation, and testing services designed to meet stringent regulatory requirements. Its value proposition centers on deep CGT-specific expertise, speed, and precision, aiming to de-risk and accelerate the analytical pathway for clients moving from concept to commercialization. As a service provider, its success is tied to the growth and regulatory complexity of the broader CGT industry.

DiagnosticsGenetics & GenomicsAI / Machine Learning

Technology Platform

Integrated suite of analytical methodologies (Potency/Bioassays, Flow Cytometry, Cell-Based Assays, qPCR/dPCR, Ligand-Binding Assays & MSD) specialized for the characterization and regulatory testing of Cell and Gene Therapies.

Opportunities

The company is positioned in the high-growth cell and gene therapy (CGT) sector, where increasing regulatory complexity and a proliferation of biotech startups drive demand for specialized analytical services.
Its focus on late-stage development and BLA support targets the most valuable and technically challenging part of the CGT service market.

Risk Factors

Elevalue faces significant concentration risk as its fortunes are tied entirely to the CGT sector's health.
It also operates in a competitive landscape against large, diversified CROs and other niche players, and its service-based model is highly dependent on recruiting and retaining scarce scientific talent.

Competitive Landscape

Elevalue competes with large, full-service CROs (e.g., Labcorp, Charles River) that have dedicated CGT units, as well as other specialized analytical service providers focused on biologics and cell therapy. Its differentiation is its pure-play CGT focus, deep expertise in complex potency assays, and positioning as an end-to-end partner for the analytical regulatory pathway.